FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281538> ?p ?o ?g. }

• W4379281538 endingPage "e18009" @default.
• W4379281538 startingPage "e18009" @default.
• W4379281538 abstract "e18009 Background: Cancer vaccines may expand intratumoral CD8+ T cells, potentially increasing response rates to PD-1 blockade. SNS-301 is a bacteriophage-based cancer vaccine against aspartate β- hydroxylase (ASPH), a prevalent tumor-associated antigen. The objectives of this Phase 1/2 study were to evaluate the safety, immunogenicity and preliminary efficacy of SNS-301 plus pembrolizumab in patients (pts) not achieving tumor reductions on PD-1 blockade alone (Cohort A) or PD-1 blockade naïve patients (Cohort B). Methods: This trial enrolled SCCHN pts with locally advanced, unresectable or metastatic/recurrent ASPH + tumors per screening immunohistochemistry. Intradermal SNS-301 (1x10 11 particles) + pembrolizumab (200mg IV q3w or 400mg IV q6w) was administered to pts with stable disease (SD) or unconfirmed progressive disease on ongoing PD-1 blockade of at least 12 weeks duration in Cohort A, and anti-PD1/PD-L1 naïve patients in Cohort B. Each cohort utilized a Simon Two Stage design with ORR assessed per RECIST1.1 at 12 weeks as the primary endpoint. The null hypothesis (H 0 ) was 5% ORR for Cohort A and 13.3% for cohort B. Enrollment of stage 2 was triggered if the ORR rate was ≥ 1 out of 15 initial evaluable patients (Cohort A) or ≥2 out of 15 (Cohort B). An initial “safety run-in” was instituted to ensure safety of the combination. Blood samples were collected to evaluate B and T cell responses using ELISA and ELISPOT assays, respectively. Results: Safety. No dose-limiting toxicities were identified in the “safety run-in” (initial 3 pts dosed). Overall, 25 pts were evaluable for safety assessment. 18 pts reported at least one treatment-emergent adverse event (TEAE), the majority of which were ≤ Grade 3. Grade 3 TRAEs included pruritus, rash, dehydration and QT prolongation. Three pts discontinued the study treatment due to TEAE and none were related to study treatment. There were three deaths reported during the follow-up period of the study and none were treatment related. Efficacy. 18 pts in Cohort A and 1 pt in Cohort B were evaluable for response per RECIST1.1 at 12 weeks. In Cohort A, one patient in Stage 1 had a PR, which triggered enrollment into Stage 2. In addition, 8 patients experienced SD as the best overall response. In Cohort B, a single PD-1/PD-L1 naïve patient was evaluable for efficacy and experienced a PR on the combination. Only a single pt in Cohort A experienced an AE of special interest (Grade 1 injection site pain). Pts treated with SNS-301 + pembrolizumab did not demonstrate significant ASPH-specific T-cell responses or increases in serum ASPH antibody titers. Conclusions: The combination of SNS-301 and pembrolizumab was well-tolerated with few treatment-related TEAEs. Importantly, pts treated with SNS-301 + pembrolizumab did not demonstrate ASPH-specific antibody or T-cell responses. Based on insufficient immunologic and clinical activity, the trial was terminated early. Clinical trial information: NCT04034225 ." @default.
• W4379281538 created "2023-06-05" @default.
• W4379281538 creator A5010399375 @default.
• W4379281538 creator A5011081784 @default.
• W4379281538 creator A5015110544 @default.
• W4379281538 creator A5019539470 @default.
• W4379281538 creator A5024360451 @default.
• W4379281538 creator A5041561535 @default.
• W4379281538 creator A5043124894 @default.
• W4379281538 creator A5050138525 @default.
• W4379281538 creator A5072582710 @default.
• W4379281538 creator A5083390361 @default.
• W4379281538 creator A5087187593 @default.
• W4379281538 date "2023-06-01" @default.
• W4379281538 modified "2023-09-26" @default.
• W4379281538 title "Safety and efficacy of SNS-301 plus pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)." @default.
• W4379281538 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e18009" @default.
• W4379281538 hasPublicationYear "2023" @default.
• W4379281538 type Work @default.
• W4379281538 citedByCount "0" @default.
• W4379281538 crossrefType "journal-article" @default.
• W4379281538 hasAuthorship W4379281538A5010399375 @default.
• W4379281538 hasAuthorship W4379281538A5011081784 @default.
• W4379281538 hasAuthorship W4379281538A5015110544 @default.
• W4379281538 hasAuthorship W4379281538A5019539470 @default.
• W4379281538 hasAuthorship W4379281538A5024360451 @default.
• W4379281538 hasAuthorship W4379281538A5041561535 @default.
• W4379281538 hasAuthorship W4379281538A5043124894 @default.
• W4379281538 hasAuthorship W4379281538A5050138525 @default.
• W4379281538 hasAuthorship W4379281538A5072582710 @default.
• W4379281538 hasAuthorship W4379281538A5083390361 @default.
• W4379281538 hasAuthorship W4379281538A5087187593 @default.
• W4379281538 hasConcept C121608353 @default.
• W4379281538 hasConcept C126322002 @default.
• W4379281538 hasConcept C141071460 @default.
• W4379281538 hasConcept C143998085 @default.
• W4379281538 hasConcept C2776530083 @default.
• W4379281538 hasConcept C2776833033 @default.
• W4379281538 hasConcept C2777701055 @default.
• W4379281538 hasConcept C2780057760 @default.
• W4379281538 hasConcept C71924100 @default.
• W4379281538 hasConcept C72563966 @default.
• W4379281538 hasConceptScore W4379281538C121608353 @default.
• W4379281538 hasConceptScore W4379281538C126322002 @default.
• W4379281538 hasConceptScore W4379281538C141071460 @default.
• W4379281538 hasConceptScore W4379281538C143998085 @default.
• W4379281538 hasConceptScore W4379281538C2776530083 @default.
• W4379281538 hasConceptScore W4379281538C2776833033 @default.
• W4379281538 hasConceptScore W4379281538C2777701055 @default.
• W4379281538 hasConceptScore W4379281538C2780057760 @default.
• W4379281538 hasConceptScore W4379281538C71924100 @default.
• W4379281538 hasConceptScore W4379281538C72563966 @default.
• W4379281538 hasIssue "16_suppl" @default.
• W4379281538 hasLocation W43792815381 @default.
• W4379281538 hasOpenAccess W4379281538 @default.
• W4379281538 hasPrimaryLocation W43792815381 @default.
• W4379281538 hasRelatedWork W2020823099 @default.
• W4379281538 hasRelatedWork W2963491961 @default.
• W4379281538 hasRelatedWork W2980510993 @default.
• W4379281538 hasRelatedWork W3000701650 @default.
• W4379281538 hasRelatedWork W3090002302 @default.
• W4379281538 hasRelatedWork W3103265772 @default.
• W4379281538 hasRelatedWork W3154280247 @default.
• W4379281538 hasRelatedWork W3210496311 @default.
• W4379281538 hasRelatedWork W4323657820 @default.
• W4379281538 hasRelatedWork W4377238167 @default.
• W4379281538 hasVolume "41" @default.
• W4379281538 isParatext "false" @default.
• W4379281538 isRetracted "false" @default.
• W4379281538 workType "article" @default.